| scholarly article | Q13442814 |
| P50 | author | Anne-Marie Mes-Masson | Q30002003 |
| Benjamin Haibe-Kains | Q38639014 | ||
| Thomas Karn | Q40714980 | ||
| Cécile Le Page | Q90769606 | ||
| P2093 | author name string | Diane Provencher | |
| John Stagg | |||
| Joshy George | |||
| Isabelle Cousineau | |||
| Sandra Pommey | |||
| Martin Turcotte | |||
| Deena M A Gendoo | |||
| Gregory M Chen | |||
| Guillaume Chouinard | |||
| Kathleen Spring | |||
| Kurosh Rahimi | |||
| P2860 | cites work | Cancer statistics, 2009 | Q29547625 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 4494-4503 | |
| P577 | publication date | 2015-09-11 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | CD73 is associated with poor prognosis in high-grade serous ovarian cancer | |
| P478 | volume | 75 |
| Q26749571 | A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment |
| Q52716939 | A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment. |
| Q37390796 | A network-pathway based module identification for predicting the prognosis of ovarian cancer patients |
| Q38740257 | A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor |
| Q47996955 | Angiogenesis inhibitors in early development for gastric cancer. |
| Q36709157 | Anti-CD73 in cancer immunotherapy: awakening new opportunities. |
| Q36771997 | Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model |
| Q38971795 | Approaches for targeting cancer stem cells drug resistance |
| Q52649982 | CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. |
| Q90066203 | CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts |
| Q47630700 | CD73 expression in lymph node metastases in patients with head and neck cancer |
| Q37641666 | CD73 is associated with poor prognosis in HNSCC. |
| Q92932103 | CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint |
| Q64055633 | CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q37012714 | CD73-adenosine reduces immune responses and survival in ovarian cancer patients |
| Q38711094 | CD73-adenosine: a next-generation target in immuno-oncology |
| Q37624627 | CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer |
| Q40783577 | CD73s protection of epithelial integrity: Thinking beyond the barrier. |
| Q42509183 | Cellular Migration Ability Is Modulated by Extracellular Purines in Ovarian Carcinoma SKOV-3 Cells. |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q55001315 | Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. |
| Q64094669 | Downregulation of CD73 associates with T cell exhaustion in AML patients |
| Q49791703 | Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings |
| Q52611870 | Exomechip Analyses Identify Genes Affecting Mortality after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. |
| Q92783224 | Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity |
| Q48193659 | Extracellular nucleosides and nucleotides as immunomodulators |
| Q38951943 | From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. |
| Q48150041 | Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface. |
| Q49920182 | Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients |
| Q92513092 | Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors |
| Q38842511 | Immunotherapy for oesophagogastric cancer |
| Q91950939 | Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future |
| Q90623679 | Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites |
| Q33630440 | MicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73. |
| Q56891008 | Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma |
| Q46026307 | Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. |
| Q64262635 | NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer |
| Q92637629 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy |
| Q46047154 | New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone |
| Q37677827 | Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). |
| Q39157893 | Pathological overproduction: the bad side of adenosine. |
| Q38765118 | Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging |
| Q89726333 | Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC |
| Q39130451 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy |
| Q41342104 | Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review |
| Q37702792 | Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer |
| Q59793963 | Purinergic targeting enhances immunotherapy of CD73 solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells |
| Q92306380 | Rational combinations of immunotherapy with radiotherapy in ovarian cancer |
| Q37456596 | STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. |
| Q39235260 | Targeting adenosine in cancer immunotherapy: a review of recent progress. |
| Q46140918 | Targeting immunosuppressive adenosine in cancer |
| Q34550649 | Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy |
| Q92259261 | The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors |
| Q96230894 | The adenosine pathway in immuno-oncology |
| Q38964974 | The development of targeted new agents to improve the outcome for children with leukemia |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q87844656 | The expression of the MSC-marker CD73 and of NF2/Merlin are correlated in meningiomas |
| Q39456999 | The immune contexture in cancer prognosis and treatment |
| Q49787788 | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
| Q42378844 | Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers |
| Q47141380 | Tregs: Where We Are and What Comes Next? |
| Q87944215 | [B cells in head and neck oncology] |
Search more.